Glenmark Pharma. Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹4,247 Cr −29.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
GP

Glenmark Pharma.

Q4 FY26Pharmaceuticals & Biotechnology

Glenmark Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹3,771Cr
+15.8% YoY
−3.3% QoQ
Net profit
₹301Cr
+7425% YoY
−25.3% QoQ
Margin
20%
+3 pp YoY
−2 pp QoQ
Price₹2,475
Market cap₹69.1K Cr
P/E22.1

The short version

Future growth expectations for Glenmark Pharmaceuticals are as follows: - FY27 revenue guidance targets between INR 17,000 crores to INR 18,000 crores with an EBITDA margin of 21-22%. Glenmark expects a strong FY27 with revenue guidance of INR 17,000 to 18,000 crores and an EBITDA margin of 21% to 22%, considering growth investments and geopolitical factors.

From Glenmark Pharma.'s Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Future growth expectations for Glenmark Pharmaceuticals are as follows: - FY27 revenue guidance targets between INR 17,000 crores to INR 18,000 crores with an EBITDA margin of 21-22%. - Strong growth anticipated across all markets, driven by: - U.S. business ramp-up with respiratory product launches including Fluticasone nasal spray, MDI inhalers, and two sole FTFs launching in Q3 and Q4. - Expansion in India and Emerging Markets with oncology portfolio launches (Aumolertinib, Trastuzumab Rezetecan, Envafolimab) and strong performance in branded segments like RYALTRIS. - Continued 7-8% of sales reinvestment in R&D fueling innovation and pipeline growth. - RYALTRIS expected to grow over 30-40% for the next few years, expanding into markets like Brazil and China.

2 more points from Glenmark Pharma.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Glenmark Pharma. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Glenmark has set aside $70 million for future spend related to IGI (Innovative Generics & Injectables) pipeline.
  • R&D expenditure is planned at 7% to 8% of sales to support innovation and growth drivers.
  • Capital allocation for FY27 is largely focused on expansion of core businesses, including therapeutic areas like respiratory, dermatology, oncology, and branded generics.
  • FY26 capex included significant intangible assets additions (~INR 800 crores) due to upfront payments and milestones related to strategic in-licensing and partnerships for innovative business and U.S. injectables.
  • From FY27 onwards, capex is expected to normalize around INR 900 crores, reflecting a return to more typical investment levels.

2 more points from Glenmark Pharma.'s call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Glenmark Pharma. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights related to business growth and expected launches include: - Strong growth anticipated in FY27 driven by launches in the U.S., India, and emerging markets. - Expansion in core businesses with capital allocation focused on growth and innovation. - New product launches including multiple respiratory products in the U.S. and oncology therapies in India and emerging markets.

2 more points from Glenmark Pharma.'s call on order book

Create a free account to keep reading this call

Glenmark Pharma. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Glenmark Pharma. Q4 FY26 results — key figures

Glenmark Pharma. Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue3,7713,256+15.8%3,901-3.3%
Operating profit (EBITDA)763561+36%870-12.3%
Operating margin20%17%+3 pp22%-2 pp
Profit before tax3888+4750%534-27.3%
Net profit (PAT)3014+7425%403-25.3%
EPS (₹)10.680.16+6575%14.29-25.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.2K Cr, net profit ₹264 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Glenmark Pharma. and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Glenmark Pharma. Q4 FY26 results?

Future growth expectations for Glenmark Pharmaceuticals are as follows: - FY27 revenue guidance targets between INR 17,000 crores to INR 18,000 crores with an EBITDA margin of 21-22%. Glenmark expects a strong FY27 with revenue guidance of INR 17,000 to 18,000 crores and an EBITDA margin of 21% to 22%, considering growth investments and geopolitical factors.

What is Glenmark Pharma. share price analysis?

Glenmark Pharma. currently shows a neutral. The stock trades at a P/E of 22.1 with a market cap of ₹69,072 Cr. Investors should review the full earnings analysis for detailed insights.

Is Glenmark Pharma. planning capital expenditure?

Glenmark has set aside $70 million for future spend related to IGI (Innovative Generics & Injectables) pipeline. - R&D expenditure is planned at 7% to 8% of sales to support innovation and growth drivers. - Capital allocation for FY27 is largely focused on expansion of core businesses, including therapeutic areas like respiratory, dermatology, oncology, and branded generics. - FY26 capex included significant intangible assets additions (~INR 800 crores) due to upfront payments and milestones related to strategic in-licensing and partnerships for innovative business and U.S.

Keep Glenmark Pharma. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.